Although TMZ initially exhibits therapeutic potential, over 50% of GBM patients develop profound TMZ resistance, associated with O6-methylguanine-DNA methyltransferase (MGMT) methylation, isocitrate dehydrogenase (IDH) mutations, 1p/19q co-deletion status, and aberrant signaling cascades, ultimately leading to disease progression and mortality [7–9]. The gene discussed is MGMT; the disease is glioblastoma.